SINOPHARM GROUP CO. LTD. Interim Results 2023
Presentation
Content
Ch.I Interim Results Review
Ch.II Macro Economy and Industry Policies
Ch.III Business Highlights and Future Strategies
Accelerating Benefits of Scale and Steady Increase in Market Share
Revenue
+15.1%
300,950.28
261,471.72
2022 1H | 2023 1H |
Net Profit Attributable to
Owners of Parent
+11.12%
4,104.44
3,693.74
2022 1H | 2023 1H |
Net Profit
+10.67%
6,893.23
6,228.62
2022 1H | 2023 1H |
Proportion of Revenue from
Each Business Segment
-0.32P.P
72.69% | 72.37% | 2022 1H | ||
+0.35P.P | 2023 1H | |||
19.86% | +0.03P.P | -0.06P.P | ||
20.21% | ||||
5.65% 5.68% | 1.8% | 1.74% | ||
Pharmaceutical Medical Device Retail Pharmacy | Others | |||
Distribution |
Unit: RMB million
Optimizing Operational Efficiency and Decrease in Expenses Ratio Indicators
Selling Expenses Ratio
- 0.17p.p
2.97 %
2.80 %
2022 1H | 2023 1H |
Financial Expenses Ratio
-0.14p.p
0.61%
0.47%
Administrative Expenses Ratio
- 0.08p.p
1.4%
1.32%
2022 1H | 2023 1H |
Overall Expenses Ratio
-0.39P.P
4.98%
4.59%
2022 1H | 2023 1H | 2022 1H | 2023 1H |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Sinopharm Group Co. Ltd. published this content on 28 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 August 2023 02:18:01 UTC.
